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INTRODUCTION
Fibromyalgia syndrome (FMS) is a commonchronic condition of widespread pain with
causal mechanisms that are largely unknown. It is
characterized by moderate to severe musculoskel -
etal pain and allodynia, but its pathogenesis ap-
pears confined to the nociceptive structures of the
central nervous system. 
From a pathogenetic point of view, indeed, no clear
muscle pathology has been demonstrated in FMS
(1, 2), while increasing evidence suggests a distur-
bance in pain perception that is genetically condi-
tioned. In our review we will consider five “key-
points” that we think determine the origin and
maintenance of the pain syndrome that we define
as fibromyalgia: “triggers,” “genetics,” “central
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RIASSUNTO
La sindrome fibromialgica (FMS) è una comune condizione cronica di dolore diffuso con meccanismi causali larga-
mente sconosciuti, ma la sua patogenesi appare associata ad una alterazione del sistema nocicettivo a livello del si-
stema nervoso centrale. La FMS è spesso scatenata da influenze ambientali negative, specialmente se presenti nell’in-
fanzia. In un feto, questi triggers ambientali possono influenzare lo sviluppo del sistema nervosa autonomo (ASN) e
dell’asse ipotalamo-ipofisi-surrene (HPA). Frequente è la comorbidità di condizioni psicologiche che comprendono
la depressione, gli attacchi di panico, l’ansia e il disturbo post-traumatico da stress (PTSD). Recenti evidenze sugge-
riscono che fattori genetici possano giocare un ruolo nella patogenesi della FMS. La sensibilizzazione centrale è sta-
ta da tempo associata con il dolore fibromialgico. Questo fenomeno descrive l’aumentata eccitabilità dei neuroni del-
le corna dorsali, che porta alla trasmissione di alterate informazioni nocicettive al cervello. La comprensione delle
vie patogenetiche della FMS è supportata dall’osservazione delle risposte dei pazienti alle terapie neurofisiologica-
mente mirate e dalla ricerca di base.
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sensitization,” “neuroendocrine abnormalities” and
“nervous autonomic amplification.” (Fig. 1).
The “triggers”
Fibromyalgia is often triggered by negative envi-
ronmental influences, especially if they occur in
childhood. In a fetus, these environmental triggers
may influence the development of the autonomic
nervous system (ANS) and the hypothalamic-pitu-
itary-adrenal axis (HPA), which represent the key
components of the neuroendocrine response to
stressors. Their functional alteration constitutes the
main factor that predisposes individuals to devel-
op many stress-related diseases in adulthood, in-
cluding FMS (3).
Low birth weight also correlates with hyperactivi-
ty of the HPA in males and sympathetic hypertone
in females; therefore, it seems that these individu-
als have a more intense cardiovascular response to
stressors (4). A history of childhood adversity, vi-
olence or stressors may cause a higher incidence of
certain co-morbid conditions in adult patients with
FMS such as major depression (5, 6). 
Likely the reaction to the stress induced by these
traumatic events, which occurs in a critical period
for the development of specific synapses, induces
alterations in the central nervous system (7).
Although a direct causal relationship between in-
fectious diseases and FMS has not been demon-
strated, it seems reasonable, however, that infec-
tions can, in some way, act as triggering agents.
The onset of FMS, in fact, has been allied with
multiple vaccinations for infectious diseases, virus-
es or bacteria (8). It is possible that the hypotheti-
cal infectious, natural or attenuated agent acts by
indirectly stimulating production of cytokines that
take part in the multiple physiological functions
that are altered in patients with FMS. 
Evidence supports a high prevalence of FMS
among patients with numerous chronic infections,
including Epstein Barr virus, herpes 6-virus, HIV
and, recently, HTLV-I virus (9, 10).
Sleep disturbance could trigger mechanisms of
FMS. Moldofsky (11), in fact, artificially repro-
duced fibromyalgia-like symptomatology in
healthy volunteers by using an acoustic stimulus of
an intensity that was insufficient to provoke awak-
ening yet was able to disturb non-REM sleep. How-
ever, just as altering sleep physiology can induce
the appearance of musculoskeletal pain, the inverse
is also true: nociceptive muscular stimulation ap-
plied to healthy volunteers during sleep can alter
EEG patterns (12).
The risk of developing FMS seems to be increased
in patients with chronic painful conditions of an-
other nature; more than 80% of patients, in fact, re-
port that they have suffered from a chronic local-
ized painful condition before the generalization of
pain (13). In patients affected by symptomatic hip
osteoarthritis abnormalities of the inhibitory system
for nociception, similar to that documented in FMS
patients, have been found; these abnormalities nor-
malize following successful prosthetic treatment
of the hip (14). Nociceptive persistent inputs are
sufficiently intense; therefore, they could induce
the generalization of pain and insurgence of FMS
in predisposed subjects.
A particular sensitivity to multiple chemical sub-
stances would be the cause of multiple chemical
sensitivity syndrome, a dysfunctional syndrome
that is closely associated with FMS and chronic
fatigue syndrome. Mercury, nickel, and silicone,
which is commonly used in surgical breast im-
plants, are substances that are frequently cited as
possible causes of dysfunctional syndromes, such
as FMS (15, 16).
Of particular importance as triggers of FMS are
psychological conditions that can lead to catastro-
phizing of pain (17, 18) or life events and, there-
fore, cause additional stress. There is increasing
evidence supporting the comorbidity of FMS and
psychological conditions. These conditions include
depression, panic disorders, anxiety, and post-trau-
matic stress disorder (PTSD). The nature of the re-
lationship between depression and FMS is not ful-
ly understood. Depression is a common denomi-
nator among chronic painful conditions (15); it has
been hypothesized that chronic pain causes de-
pression, or vice versa, and that chronic pain syn-
dromes are variants of depression. A link between
PTSD symptoms and FMS has been reported, and
both conditions share similar symptomatology and
pathogenetic mechanisms (19). 
The preexistence of chronic stressful conditions
prior to the onset of FMS is frequently demon-
strated. The symptomatology that is reported by fi-
bromyalgia patients seems to be influenced nega-
tively by chronic stressful situations, while positive
correlations with acute stressful events have not
been found (20). In addition, FMS patients show
higher levels of stress compared to controls (21).
Genetics
Recent evidence suggests that genetic factors may
play a role in the pathogenesis of FMS (22-24).
Certain environmental factors (“stressors”) may
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trigger the development of FMS in genetically pre-
disposed individuals (25).
A number of studies published over recent years
have documented increased incidence of FMS
among family members of patients suffering from
this syndrome (26-28). 
Buskila et al. found that 28% of offspring of FMS
patients fulfill the American College of Rheuma-
tology (1990) classification criteria for the diagno-
sis of FMS (26). Buskila et al. reported another
study, we reported that the prevalence of FMS
among blood relatives of patients with FMS was
26%, and that FMS prevalence in male and female
relatives was 14% and 41%, respectively (27).
Arnold and colleagues (28) tested the hypotheses
that FMS and measures of pain and tenderness ag-
gregate in families and that FMS co-aggregates
with major mood disorder. They performed a fam-
ily interview study of 78 probands with FMS and
40 probands with rheumatoid arthritis (RA). They
assessed FMS and major mood disorder in a total
of 533 first degree relatives of FMS probands and
a total of 272 first degree relatives of RA probands.
FMS was found to aggregate strongly in families: the
odds ratio measuring the odds of FMS in a relative
of a proband with FMS versus the odds of FMS in
relative of a proband with RA was 8.5. The clear fa-
milial aggregation in FMS and related conditions
may represent either genetic or environmental in-
fluence, or most likely a combination of both.
Based on the strong evidence of a familial aggre-
gation in FMS, a considerable amount of research
has been conducted in search of the genetic un-
derpinnings of this phenomenon. At present no ev-
idence has emerged to suggest a monogenic mode
of transmission, and a multifactorial mode of trans-
mission is generally presumed. 
Research done in recent years has demonstrated a
role for polymorphisms of genes in the serotoner-
gic, dopaminergic and catecholaminergic systems
in the etiology of FMS.
Offenbaecher and colleagues (29) analyzed the
genotypes of the promoter region of the serotonin
transporter gene (5-HTT) in 62 patients with FMS
and 110 healthy controls. A significantly higher
frequency of the S/S genotype of the serotonin
transporter promoter region was found in FMS pa-
tients (31%) compared with healthy controls
(16%). The S/S subgroup exhibited higher mean
levels of depression and psychological distress. It
was suggested that the results support the notion of
altered serotonin metabolism in at least a subgroup
of patients with FMS.
In another study, these researches reported on a
significantly different genotype distribution in FMS
patients with a decrease in T/T and an increase in
both T/C and C/C genotypes compared to the con-
trol population (30). 
Cohen and colleagues (31) performed genotyping
in a group of 99 female FMS patients from two Is-
raeli ethnic groups. Additionally, each patient was
assessed with the Tridimensional Personality Ques-
tionnaire (TPQ). The results of this study confirm
the association between FMS and the serotonin
transporter promoter region (5 - HTTLPR) poly-
morphism in two ethnic groups in Israel, Jewish
and Bedouins. A significant association between 5
- HTTLPR polymorphism and anxiety-related per-
sonality traits was found as well (31).
Zubieta and colleagues (32) examined the influ-
ence of a common functional genetic polymor-
phism affecting the metabolism of catecholamines
on the modulation of responses to sustained pain
in humans. Individuals homozygous for the Met
158 allele of the catechol - O methyltransferase
(COMT) polymorphism (Val 158 Met) show di-
minished regional mu-opioid system responses to
pain compared with heterozygotes. These effects
were accompanied by higher sensory and affective
ratings of pain and a more negative internal affec-
tive state. 
It was concluded that the COMT Val 158 Met poly-
morphism influences the human experience of pain
and may underlie interindividual differences in the
adaptation and responses to pain and other stress-
ful stimuli (32).
Gursory and colleagues (33) have reported on the
involvement of COMT gene polymorphism in pa-
tients with FMS. Recently, Vargas-Alarcon et al.
(35) reported that in a group of Spanish patients,
there was an association between FMS and the
COMT haplotype. However, this association was
not observed in Mexican patients.
Buskila and colleagues (35) reported a significant
decrease in the frequency of the 7 repeat allele in
exon III of the DR receptor gene in FMS patients
and also demonstrated an association between the
polymorphism and the low novelty seeking per-
sonality trait. Altogether, recent evidence suggests
a role for polymorphism of genes in the serotoner-
gic, dopaminergic and catecholaminergic systems
in the etiopathogenesis of FMS.
Thus recent evidence suggests a role for genetic
and familial factors in the development of FMS.
The mode of inheritance in FMS is unknown, but
it is most probably polygenic. Recognition of these
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gene polymorphisms may help to better subgroup
FMS patients and to guide a more rational phar-
macologic approach.
Central sensitization
Central sensitization has long been considered to be
associated with FMS pain (36) (Fig. 1). It describes
enhanced excitability of dorsal horn neurons, then
transmission of altered nociceptive information to
the brain. “Wind-up“ (temporal summation) is the
second mechanism increasing pain: a painful stim-
ulus is applied steadily but the pain is perceived as
increasing in intensity while applied subsequently
(37, 38). Receptor fields increase as well, resulting
in a larger distribution of the pain (39-41).
These phenomena of functional neuroplasticity are
predominantly mediated by activation of N-methyl-
D-aspartate (NMDA) receptors (42-44). Persistent
activation of NMDA receptors may lead into struc-
tural alterations/reorganisation of the whole dorsal
horn synapse. Again, the result may be chronic
spinal amplification of the nociceptor input.
A descending pain inhibitory system originates in
neurons of the periaqueductal gray matter, with de-
scending projections to the nucleus raphe magnus
and other nuclei in the rostral medulla. The neurons
in these nuclei project via the dorsolateral funicu-
lus to the spinal dorsal horn with projections in dif-
ferent nuclei of the rostral medulla, where they in-
hibit nociceptive neurons by releasing (among oth-
er neuropeptides) serotonin. But also noradrener-
gic neurons in the medulla are involved. NE and 5-
HT are key neurotransmitters in descending in-
hibitory pain pathways. Increasing the availability
of NE and 5-HT may promote pain inhibition cen-
trally (45-48).
As the system acts predominantly on the nocicep-
tive input from deep tissues, an impairment of the
descending inhibition will increase the ongoing ac-
tivity and excitability particularly in dorsal horn
neurons that process information from deep noci-
ceptors. In patients, this may result in spontaneous
pain and tenderness mainly in deep tissues. As the
terminations of the descending neurons have a
widespread distribution in the spinal cord, a dys-
function of the descending system may result in, or
contribute to, the symptom of widespread pain ob-
served in FMS (49).
A recent study by Harris et al. (50) compared a sam-
ple of 17 FMS patients and 17 age- and sex-matched
healthy controls using mu-opioid receptor (MOR)
positron emission tomography. It demonstrated that
FMS patients display reduced MOR within several
regions that play an important role in pain regula-
tion, such as the nucleus accumbens, the dorsal cin-
gulate, and the amygdala. These results indicate al-
tered endogenous opioid analgesic activity in FMS
and explain why exogenous opiates appear to have
reduced efficacy in this population.
A previous study by the same group (51) suggested
that pain catastrophizing is significantly associated
with increased activity in some brain areas related
to anticipation of pain (medial frontal cortex, cere-
bellum), attention to pain (dorsal ACC, dorsolater-
al prefrontal cortex), and emotional aspects of pain
(claustrum, closely connected to amygdala). These
results suggest that catastrophizing influences pain
perception by altering attention and anticipation,
and heightening emotional responses to pain. 
Also some neurotransmitters play an important role
in the central sensitization of the widespread pain
that characterizes FMS. Serotonin is crucial in me-
Figures 1 - Modified from Van Houdenhove (106) - and 2 synthesize our proposal for the pathogenesis of FMS. From exposed it’s probable that
triggers cause a central sensitization when they interact in genetically predisposed individuals. Then central sensitization creates a vicious cir-
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diating pain pathways; it was the first neuropeptide
to be studied extensively in FMS and hypothesized
to be involved in abnormal pain processing (52,
53). The co-morbidity of psychiatric conditions,
such as depression, and the alterations of sleep-
wake cycles, mediated by 5-HT, seemed to sup-
port 5-HT dysregulation (54).
Levels of 5-HT, its precursor tryptophan, and its
metabolites 5-HIAA and 5-HTP were measured in
the blood, in the cerebrospinal fluid (CSF), and in
the urine of FMS patients. The most consistent re-
sults of all attempts to confirm an abnormality in
5-HT neurotransmission were derived from CSF
samples. The pioneering studies did not measure 5-
HT directly but found decreased levels of 5-HIAA
in FMS patients as compared to controls, includ-
ing both pain-free and low back pain subjects (55-
57). The results from studies measuring 5-HT lev-
els in the serum of patients with FMS were less
consistent. One group documented higher 5-HT
levels in FMS patients versus controls (58), even
using platelet-rich plasma for the assay, whereas
another group found lower serum 5-HT levels in
FMS than in RA patients (54). The hypothesis was
that increased platelet activation may lead to a re-
lease of 5-HT into the plasma fraction. FMS pa-
tients with a high plasma-to-serum 5-HT ratio pre-
sented with a higher frequency of orofacial pain
and anxiety (59). Similarly in another study, the
number of tender points and serum 5-HT levels
significantly correlated inversely, comparing FMS
patients with both RA patients and healthy con-
trols (52). Whether or not the inconsistency may be
explained by changes within the serotonin trans-
porter has been discussed. A polymorphism in the
5-HT transporter gene regulatory region (S/S geno-
type) is associated with decreased 5-HT transporter
messenger RNA transcription and decreased 5-HT
uptake in vitro. As mentioned previously, this poly-
morphism has been shown to have a significantly
higher distribution in FMS cohort (29). 
To summarize, a dysregulation of 5-HT metabo-
lism in FMS is likely but has not been proven to be
the sole cause of central sensitization of FMS.
Substance P, an 11-amino-acid neuropeptide, acts
as a neuromodulator via the NK1 receptor. It sen-
sitizes the neurons to the effects of other neuro-
modulators. Stimulating the release of 5-HT in the
spinal cord decreases the release of substance P in-
to the spinal cord (60).
Substance P levels in the CSF of FMS patients have
been found to be reproducibly high in five differ-
ent studies (61-64). A trend toward correlation of
CSF substance P levels and pain severity in FMS
over time has been suggested (65). Other chronic
pain states, such as low back pain and painful neu-
ropathy, present with low levels of CSF substance
P (66-69). High CSF concentration of substance P
represents the most prominent neurochemical ab-
normality found in FMS patients.
There are significant negative correlations between
levels of substance P and 5-HT, its precursor tryp-
tophan (TRP), and its primary metabolite 5-HIAA
in the serum of patients with FMS. High serum
concentrations of 5-HIAA and TRP showed a sig-
nificant relation to low pain scores. Low levels of
5-HIAA and high concentrations of substance P
were both positively correlated with more severe
sleep disturbance (70). Nerve growth factor (NGF),
which stimulates the production of substance P in
small, afferent, unmyelinated neurons, was found
to be elevated in the CSF of FMS patients with pri-
mary FMS, but not in FMS with an associated
painful inflammatory condition (secondary FMS)
(71). This finding addresses the clinical finding of
subgroups in FMS (72-74). Elevated CSF sub-
stance P could be a common link between prima-
ry and secondary FMS, but the groups differ with
regard to the mechanism responsible for the ele-
vated substance P. In primary FMS, NGF seems to
induce the elevated CSF substance P from central
interneurons. In secondary FMS, the peripheral in-
flammation, so characteristic of the underlying
rheumatic or infectious conditions, may be re-
sponsible for the elevated CSF substance P. For
these reasons, NGF could be critical to the initia-
tion or perpetuation of the painful symptoms of
primary but not secondary FMS (71).
Neuroendocrine abnormalities
The neuroendocrine system, together with the au-
tonomic nervous system and immune system, plays
a fundamental role in the maintenance of the home-
ostasis of the organism in a large variety of envi-
ronmental situations, namely stressful events of
both physical and psychological origin. FMS is fre-
quently associated with a rich history of stress-
ful/traumatic events (75) and is characterized by a
number of symptoms similar to those typical of
stress-related conditions, such as irritable bowel
syndrome or chronic fatigue syndrome.
The hypothalamic-pituitary-adrenal axis 
(HPA-axis)
FMS patients have been shown to present with
HPA axis alterations (76-80). Compared to con-
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trols, they present low 24-h serum cortisol levels;
abnormal circadian pattern of cortisol concentra-
tion and blunted serum cortisol responses to corti-
cotropin-releasing hormone (CRH), i.e., when
CRH is released by the hypothalamus, there is a
disproportionately high release of corticotrophin
by the pituitary gland and disproportionately small
release of cortisol by the adrenal gland. This latter
result suggests an abnormal response of FMS pa-
tients to stress, and thus, an inadequate reaction to
a number of stressful events, such as trauma or in-
fection (81). Interestingly, when synthetic CRH is
injected in FMS patients this abnormal response is
not present, and the patients behave like normal
control subjects. This suggests that there might be
a different sensitivity of adrenal tissue to endoge-
nous and exogenous CRH in FMS. On the whole,
however, there is no evidence to support any struc-
tural abnormality in the endocrine organs which
comprise the HPA axis; thus, it seems that the
changes found in hormone production under acti-
vation of the axis are functional in patients with
FMS (82).
Dysregulation of the HPA axis can potentially ac-
count for several symptoms in FMS, including fa-
tigue, primarily, as well as depression and sleep
disturbance; these symptoms are often present in
subjects with a reduced activity of the axis (as in
withdrawal from glucocorticoid therapy, or in Ad-
dison’s disease) or in individuals with genetically
altered HPA axis function (83). A link with pain is
also present. For instance, a recent study by
McLean et al. (84) showed a significant association
between levels of CRH in CSF and pain levels in
patients with FMS. 
Increased central levels of CRH also produce anal-
gesia in animals (85). Activation of the HPA axis
stimulates the release of the opioid beta-endorphin,
corticotrophin, and cortisol, which, thanks to its
anti-inflammatory properties, has the potential of
reducing pain (83), though it should be underlined
that in FMS, specifically, corticosteroids are not
effective (86).
The hypothalamic-pituitary-thyroid axis 
(HPT-axis)
The hypothalamic-pituitary-thyroid axis function
would seem altered in FMS patients as the release
of thyrotropin-releasing hormone stimulates less
thyrotropin, triiodothyronine and thyroxin produc-
tion than normal. This is possibly the result of some
pituitary dysfunction secondary to the document-
ed impaired stress response in FMS (87).
The hypothalamic-pituitary-gonadal axis 
(HPG-axis)
Though not many studies have been performed in
this area, the results of those available so far pro-
vide no evidence for any abnormality in go-
nadotropin secretion or gonadal steroid levels in
FMS (88, 89). Thus a deficit of sex hormones does
not appear to be part of the manifestations of FMS.
Growth hormone (GH)
A number of research studies have been devoted to
evaluation of circulating levels of growth hormone
in FMS. These levels tend to be normal during
waking hours and are slightly reduced during sleep.
It is well known that stage 4 of sleep is disrupted
in FMS, and this is the phase when GH is secret-
ed; it remains to be established if the decreased
GH is the consequence of disrupted sleep or of a
decreased GH-stimulation by sleep. FMS patients
have increased levels of corticotrophin, and corti-
cotrophin increases hypothalamic somatostatin se-
cretion. Since somatostatin is one of the hormones
that inhibits GH via the hypothalamic-pituitary por-
tal system this may also contribute to their relative
GH insufficiency. Supplementation with GH has
provided relatively positive results, at least in a
subpopulation of FMS patients; however, the high
costs of the hormone, combined with the unpleas-
antness of the modality of administration do not en-
courage the use of this therapy on a large scale
(90). 
FMS patients have been shown to present with
many neurochemical alterations, e.g., norepineph-
rine deficit, lower concentrations of beta-endorphin
in peripheral blood mononuclear cells (91), low
serum serotonin levels and low level of the sero-
tonin metabolite (5-HIAA) (92) in the CSF, in-
creased levels of substance P and nerve growth fac-
tor (NGF) - a promoter of substance P synthesis -
in CSF (93, 94), abnormal dopaminergic transmis-
sion. Regarding the latter, a recent review by Wood
(95) focused on the mesolimbic dopaminergic sys-
tem as a possible contributor to central pain states;
in animals acute stress activates mesolimbic
dopamine neurons inducing analgesia; however,
prolonged stress decreases mesolimbic dopamin-
ergic output and creates a hyperalgesic state. A re-
cent study by Malt et al (96) compared the response
of female patients with FMS and healthy controls
to buspirone, showing an increased prolactin re-
sponse in the FMS group, a result that was attrib-
uted by the researchers to altered dopamine sensi-
tivity in FMS. 
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Collectively, these neurotransmitter abnormalities
may play a role in HPA function and control in FMS
(97).
To date, however, the means by which HPA axis
dysfunction develops in FMS still remains unclear.
Autonomic nervous system (ANS) 
amplification
The ANS is the principal regulatory system of the
body; it maintains essential involuntary functions,
e.g., the vital signs (blood pressure, pulse, respira-
tion, and temperature) and balances the function of
all internal organs. It is a complex network acti-
vated by nerve centers located in the spinal cord,
brain stem, hypothalamus and thalamus; centers
that also receive input from the limbic area and
other higher brain regions. 
Emotions such as fear or anger, therefore, produce
immediate biological responses, such as pupil di-
latation or tachycardia. Through their neurotrans-
mitters (catecholamines for the sympathetic sys-
tem), the two divisions of the peripheral autonom-
ic system, sympathetic and parasympathetic, have
antagonistic actions on most functions of the body,
but their proper balance is essential to preserve
homeostasis (98).
A number of studies have demonstrated alterations
of the ANS in FMS, the most recent ones using
methodologies such as power spectrum analysis of
heart rate variability (HRV) and tilt table test.
Vaeroy, et al. (99) demonstrated a decreased sym-
pathetic response to painful and auditory stimuli.
Studies with power spectrum analysis of HRV
showed decreased 24-h HRV with persistent noc-
turnal sympathetic hyperactivity associated with
increased number of awakenings, decreased sym-
pathetic response to several stressors and abnormal
sympathovagal responses during postural changes.
The HRV studies reflect a basal autonomic state of
hyperactivation characterized by increased sympa-
thetic and decreased parasympathetic tone (i.e., a
sympathetic basal hyperactivity with hyporeactiv-
ity) (100, 101). Abnormal HRV in FMS, consistent
with excessive sympathetic activity, especially in
women, has been reported by several investigators
(99). In a recent study, Furlan, et al. (102) investi-
gated whether FMS is characterized by alterations
in the cardiovascular autonomic response to grav-
itational stimulus (using the stepwise tilting); they
found a reduced ability to enhance the sympathet-
ic activity to the vessels and withdraw the vagal
modulation to the sino-atrial node. 
The dysautonomia in FMS would thus be charac-
terized as a sympathetic nervous system that is
persistently hyperactive but is hyporeactive to
stress. This apparent paradox (sympathetic hyper-
activity with hyporeactivity) nevertheless agrees
with the basic physiological principle showing that
chronic hyperstimulation of the beta-adrenergic
receptors leads to receptor desensitization and
down-regulation (99). It has been suggested that
the dysautonomia in FMS could be at least in part
responsible for the pain of the syndrome - similarly
to what happens in classic sympathetic-maintained
pain conditions. 
ANS dysfunction may also explain a number of
the other clinical symptoms of FMS. Due to a ceil-
ing effect, the hyperactive sympathetic nervous
system in FMS would become unable to further re-
spond to different stressors, thus explaining the
constant fatigue and morning stiffness. Relentless
sympathetic hyperactivity may explain sleep dis-
orders, anxiety, pseudo-Raynaud’s phenomenon,
sicca symptoms, and intestinal irritability. 
Further studies support the altered sympathetic
function in FMS. Anderberg, et al. (103) found
high serum levels of neuropeptide Y (NPY) in FMS
vs healthy controls, which was interpreted as a sign
of increased sympathetic activity (prolonged and/or
repeated stress) since NPY is co-released with no-
radrenaline from sympathetic neurons. Wallace, et
al. (104) showed high serum concentrations of IL-
8 in FMS vs healthy controls, another interesting
finding since IL-8 has been associated with sym-
pathetically dependent hyperalgesia. Along the
same line, Martinez-Lavin (98) showed that a sub-
cutaneous injection of noradrenaline induced pain
more frequently and with a higher intensity in FMS
patients vs RA patients or vs healthy controls.
The HPA axis and the ANS have multiple sites of
interaction. At present it is not clear if decreased
ANS activity and altered neuroendocrine function
may contribute to the pain and related symptoms
of the syndrome or if they are the consequence of
pain. 
It is frequent for FMS patients to present a history
of emotional or physical trauma before the onset of
FMS symptoms (105). Stress is known to reduce the
neuroendocrine and ANS stress response; therefore,
stressful events may represent the triggering factor
for the neuroendocrine and ANS abnormality in
FMS. However, it is also possible that the symptoms
of FMS (pain, sleep disturbance, fatigue, etc.), ex-
perienced on a chronic basis, may affect the func-
tion of the HPA axis and ASN. As a matter of fact,
a number of studies have shown that a reduction of
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stress, obtained, for instance, through relaxation
training or exercise training, produces a decrease in
the sympathetic activity (as evaluated via spectral
analysis, resting heart rate, circulating levels of cat-
echolamines). 
Pain may also explain the reduced neuroendocrine
and ANS responsiveness since there is a high level
of substance P in the CSF in FMS, and substance P
is a potent inhibitor of CRH. 
CONCLUSIONS
Understanding of pathogenetic pathways in FMS
has advanced from observing patient responses to
neurophysiologically targeted therapies and basic
research. The model of central sensitization repre-
sents the most common and most accepted hy-
potheses about the underlying mechanisms in the
pathogenesis of FMS.
SUMMARY
Fibromyalgia syndrome (FMS) is a common chronic condition of widespread pain with causal mechanisms that are large-
ly unknown. It is characterized by moderate to severe musculoskeletal pain and allodynia, but its pathogenesis appears
confined to the nociceptive structures of the central nervous system. FMS is often triggered by negative environmental
influences, especially if they occur in childhood. In a fetus, these environmental triggers may influence the development
of the autonomic nervous system (ANS) and the hypothalamic-pituitary-adrenal axis (HPA). Increasing evidence sup-
ports the comorbidity of psychological conditions including depression, panic disorders, anxiety, and post-traumatic
stress disorder (PTSD). Recent evidence suggests that genetic factors may play a role in the pathogenesis of FMS. Cen-
tral sensitization has long been associated with FMS pain. It describes enhanced excitability of dorsal horn neurons, which
leads to transmission of altered nociceptive information to the brain. Understanding of pathogenetic pathways in FMS
has advanced beyond observing patient responses to neurophysiologically targeted therapies and basic research.
Key words - Central sensitization, neuroendocrine abnormalities, genetic factors, autonomic nervous system.
Parole chiave - Sensibilizzazione centrale, alterazioni neuroendocrine, fattori genetici, alterazioni del sistema nervoso.
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